AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Part of paid clinical trials in Valhalla, New York.

Sponsor
Mitchell Cairo
Study ID
NCT04099966
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Day - 30 Years
Healthy Volunteers
Not accepted

Interventions

  • alpha beta depletion — DRUG
    donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.

Study Details

Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

Key Dates

Start date
Apr 1, 2021
Status verified
Aug 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: alpha beta cell depletion
    Matched allogeneic donor stem cells will be processed utilizing α/β CD3+/CD19+ cell depletion with the Prodigy system. Standard pre-conditioning and post-transplant motioning will be given.

Primary Outcome Measure

incidence of adverse events related to administration of α/β CD3+/CD19+ cell depleted stem cells [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York Medical CollegeValhallaNew York10595
Mitchell S Cairo, MD
[email protected]
914-594-2150
Lauren Harrison, MSN
[email protected]
6172857844

Find similar trials in Valhalla, NY

By condition
Sickle cell disease
By research site
New York Medical College· Valhalla, NY

Related Studies